3 stories mentioning HCMUpdated 14d ago
Every FINWIRES story that references HCM, newest first.
Hutchmed (HCM) reported H1 earnings Thursday of $0.09 per diluted American depositary shares, down from $2.61 a year earlier.Revenue in the six months ended June 30 fell to $278.3 million from $277.7 million a year earlier.Two analysts polled by FactSet expected $304.2 million.Price: $10.92, Change: $-0.47, Percent Change: -4.13%
Healthcare stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Ensign Group (ENSG) shares were up more than 2% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.Hutchmed (HCM) stock was up more than 6% after the company said China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.Takeda Pharmaceutical (TAK) has partnered with Insilico Medicine to use the latter's Pharma.AI platform to advance drug candidates across selected therapeutic areas, Hong Kong-listed Insilico said. Shares of Takeda Pharmaceutical were up more than 2% premarket.
Hutchmed (HCM) said Wednesday that China's National Medical Products Administration accepted the new drug application and granted priority review for sovleplenib to potentially treat warm antibody autoimmune hemolytic anemia.The company said its application was supported by data from a phase 2/3 study in China. In January, the phase 3 part of the trial met its primary endpoint of durable hemoglobin response rate within weeks 5 to 24 of treatment, the company added.The Chinese regulator also granted breakthrough therapy designation for sovleplenib in warm antibody autoimmune hemolytic anemia in March, Hutchmed said.Price: $13.49, Change: $-0.11, Percent Change: -0.77%
